home / stock / mreo / mreo news

MREO News and Press, Mereo BioPharma Group From 10/10/19

Stock Information
Company Name: Mereo BioPharma Group
Stock Symbol: MREO
Market: NASDAQ
Website: mereobiopharma.com
Menu
MREO MREO Quote MREO Short MREO News MREO Articles MREO Message Board
Get MREO Alerts

News, Short Squeeze, Breakout and More Instantly...
MREO - BBBY, FSCT, PCG and RARX among midday movers

Gainers : Ra Pharmaceuticals, Inc. (NASDAQ: RARX ) +100% . OncoSec Medical Incorporated (NASDAQ: ONCS ) +34% . ProPetro Holding Corp. (NYSE: PUMP ) +22% . Mereo BioPharma Group plc (NASDAQ: MREO ) +21% . Bed Bath & Beyond (NASDAQ: BBBY ) +20% . Caladrius Biosciences (NASDAQ: CLBS ...
MREO - Jefferies softens view on UnitedHealth in premarket analyst action

Mereo Biopharma (NASDAQ: MREO ) initiated with Outperform rating and $8 (177% upside) price target at SVB Leerink. More news on: Mereo BioPharma Group plc, The Medicines Company, UnitedHealth Group Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...

MREO - Mereo BioPharma And Leflutrozole In Hypogonadotropic Hypogonadism

Introduction Mereo BioPharma ( MREO ) is a British small-cap ($62M) biopharma developing therapeutics for rare disorders as well as endocrine and oncological diseases. MREO has a diverse pipeline including MPH-966 (alvelestat), BCT-197 (acumapimod), and OMP-305B83 (navicixizumab) for alp...

MREO - SPWR, FRO among premarket gainers

Pfenex (NYSEMKT: PFNX ) +13%  as FDA OKs Pfenex Forteo biosimilar. More news on: Pfenex Inc., Mereo BioPharma Group plc, Livongo Health, Inc., Stocks on the move, Read more ...

MREO - Mereo Bio's navicixizumab Fast Track'd for ovarian cancer; shares up 6% premarket

Thinly traded nano cap Mereo BioPharma Group (NASDAQ: MREO ) is up  6%  premarket on increased volume, albeit on turnover of only 29K shares, in reaction to Fast Track designation in the U.S. for Phase 1-stage bispecific antibody navicixizumab for heavily pretreated patients with...

MREO - Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer

LONDON and REDWOOD CITY, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company" or the "Group," a clinical stage biopharmaceutical company focused on rare diseases, today announces that the U.S. Food and Drug Administration (&#...

MREO - Mereo BioPharma's (MREO) CEO Denise Scots-Knight on 2019 Interim Financial Results and Corporate Update Conference Call

Mereo BioPharma Group plc (MREO) 2019 Interim Financial Results and Corporate Update Conference Call September 17, 2019 8:00 AM ET Company Participants Richard Jones – Chief Financial Officer Denise Scots-Knight – Chief Executive Officer Conference Call Participant...
MREO - Mereo BioPharma Group plc 2019 Q2 - Results - Earnings Call Slides

The following slide deck was published by Mereo BioPharma Group plc in conjunction with their 2019 Q2 earnings Read more ...

MREO - Mereo BioPharma Group reports 1H results

Mereo BioPharma Group (NASDAQ: MREO ): 1H GAAP EPS of -£0.22. More news on: Mereo BioPharma Group plc, Earnings news and commentary, Healthcare stocks news, , Read more ...

MREO - Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update

12-Month Topline Results from Phase 2b ASTEROID Study with Setrusumab for Osteogenesis Imperfecta (OI) Expected in Q4 2019; Positive 6-Month Data to be Featured in Late-Breaking Oral Presentation at ASBMR 2019 Conference Call Today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and REDWOOD C...
Previous 10 Next 10